基本信息
浏览量:5
职业迁徙
个人简介
Research interests
Research Funding
Bosnic-Anticevich S,Kriikos, V, Cvetkovski B, Bousquet J, Yan, K. (2018 – 2019) Improving allergic rhinitis management through the delivery of theAllergic Rhinitis Clinical Management Pathway educational module for community pharmacy. Mylan Australia, $93,600.00.
Bosnic-Anticevich S,Hespe C, Kritikos V, Michie B, Cvetkovski B (2018-2019). Inhaler technique mastery and maintenance in general medical practitioners: Easy Low Instruction Over Time (Dr ELIOT). TEVA Pharmaceuticals, ISS Program. $150,000
Armour C,Bosnic-Anticevich S,et al., (2017 – 2019) Getting asthma under control using the skills of the community pharmacist. Commonwealth Government of Australia, Department of Health. $2,199,100.
Bosnic-Anticevich S(2017-2018) Decreasing the burden of chronic lung diseases the community. Perpetual IMPACT Philanthropy. $77,834.83
Price D andBosnic-Anticevich S.(2017) Clinical Audit and Educational Program for Allergic Rhinitis in Primary Care. MEDA Pharmaceuticals, $201,050.00
Bosnic-Anticevich S,Durieux A, Carney S, Harvey R, Hellings P, Christian L,Smith P, Price D (2016-2017) Determining the burden of Allergic Rhinitis through medication management in the Australian context. MEDA Pharmaceuticals, $50,000.
Bosnic-Anticevich SZ, Kritikos V, Cvetkovaki B, Proce D, Bousquest J, Yan K. (2016 – 2017) Identifying and addressing the needs of people with allergic rhinitis in primary care in Australia (Seed Funding) MEDA Pharmaceuticals, $20,000.
Smith P,Bosnic-Anticevich S,Durieux A, Carney S, Harvey R, Hellings P, Christian L. (2016 – 2017) The burden of rhinitis in Australia. MEDA Pharmaceuticals. $63,500.International
Ryan D, Blakey J, Bosnic-Anticevich S, Buhl R, Costello R, Hellings P, Hew M, Kaplan A, Lapperre Stevens T, Price D, Roche N, Usmani O, Vrijens B.Development of a digital algorithm to predict/detect asthma exacerbations. $130,000
Mares R, Khalikulov B, Bosnic-Anticevich S, Chrystyn H, Dekhuijzen R, Fletcher M, Papi, A, Price, A, Rodriguez-Roisin (2015 – 2016). Incidence of oral thrush in COPD patients prescribed ICS as part of ICS/LABA therapy. TEVA Pharmaceuticals, $340,000.
Research Funding
Bosnic-Anticevich S,Kriikos, V, Cvetkovski B, Bousquet J, Yan, K. (2018 – 2019) Improving allergic rhinitis management through the delivery of theAllergic Rhinitis Clinical Management Pathway educational module for community pharmacy. Mylan Australia, $93,600.00.
Bosnic-Anticevich S,Hespe C, Kritikos V, Michie B, Cvetkovski B (2018-2019). Inhaler technique mastery and maintenance in general medical practitioners: Easy Low Instruction Over Time (Dr ELIOT). TEVA Pharmaceuticals, ISS Program. $150,000
Armour C,Bosnic-Anticevich S,et al., (2017 – 2019) Getting asthma under control using the skills of the community pharmacist. Commonwealth Government of Australia, Department of Health. $2,199,100.
Bosnic-Anticevich S(2017-2018) Decreasing the burden of chronic lung diseases the community. Perpetual IMPACT Philanthropy. $77,834.83
Price D andBosnic-Anticevich S.(2017) Clinical Audit and Educational Program for Allergic Rhinitis in Primary Care. MEDA Pharmaceuticals, $201,050.00
Bosnic-Anticevich S,Durieux A, Carney S, Harvey R, Hellings P, Christian L,Smith P, Price D (2016-2017) Determining the burden of Allergic Rhinitis through medication management in the Australian context. MEDA Pharmaceuticals, $50,000.
Bosnic-Anticevich SZ, Kritikos V, Cvetkovaki B, Proce D, Bousquest J, Yan K. (2016 – 2017) Identifying and addressing the needs of people with allergic rhinitis in primary care in Australia (Seed Funding) MEDA Pharmaceuticals, $20,000.
Smith P,Bosnic-Anticevich S,Durieux A, Carney S, Harvey R, Hellings P, Christian L. (2016 – 2017) The burden of rhinitis in Australia. MEDA Pharmaceuticals. $63,500.International
Ryan D, Blakey J, Bosnic-Anticevich S, Buhl R, Costello R, Hellings P, Hew M, Kaplan A, Lapperre Stevens T, Price D, Roche N, Usmani O, Vrijens B.Development of a digital algorithm to predict/detect asthma exacerbations. $130,000
Mares R, Khalikulov B, Bosnic-Anticevich S, Chrystyn H, Dekhuijzen R, Fletcher M, Papi, A, Price, A, Rodriguez-Roisin (2015 – 2016). Incidence of oral thrush in COPD patients prescribed ICS as part of ICS/LABA therapy. TEVA Pharmaceuticals, $340,000.
研究兴趣
论文共 229 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ALLERGYno. 7 (2023): 1758-1776
EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY (2023): 100340-100340
David Price,Christine Jenkins,Kerry Hancock,Rebecca Vella,Florian Heraud, Porsche Le Cheng,Ruth Murray,Sinthia Bosnic-Anticevich, Fabio Botini,Victoria Carter,Angelina Catanzariti,Joe Doan,
引用0浏览0引用
0
0
Allergyno. 5 (2023): 1169-1203
引用5浏览0引用
5
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn